The rise of Viagra and its influence on the pharmaceutical landscape presents a complicated question for shareholders. While the first sales statistics were astounding, the patent has lapsed, leading to a deluge of generic alternatives that are eroding revenue. Moreover, the sector is facing issues related to aging trends and shifting healthcare… Read More